Citrocil

Quick links to important sections

Citrocil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Citrocil

Quick Facts

Property Description
Active Ingredient Dihydrostreptomycin Sulfate
Form Powder for injection, Solution for injection
Pharmacological Class Aminoglycoside antibiotic
General Purpose Bacterial elimination (Bactericidal)
Origin Semi-synthetic (Derived from Streptomycin)

What Type of Medicine is Citrocil?

Citrocil is the trade name for a medicinal product whose active ingredient is Dihydrostreptomycin, classified as a semi-synthetic Aminoglycoside antibiotic. This medicine is derived from the naturally occurring compound Streptomycin, establishing its origin as a chemically modified version. This modification defines its role within its drug class.

The classification as an Aminoglycoside means the medicine is specifically designed to exert a decisive bactericidal effect, actively killing susceptible bacteria rather than simply inhibiting their growth. Dihydrostreptomycin is clinically recognized for its activity against certain gram-negative bacteria, defining its potent antibacterial utility.


Composition and Standard Pharmaceutical Form

The composition of Citrocil is centered around Dihydrostreptomycin Sulfate, which is formulated for direct systemic delivery. This medicine is typically prepared either as a sterile solution for injection or a powder for injection that requires reconstitution. The inherent chemical properties of the Dihydrostreptomycin molecule necessitate its intended use via the parenteral route (injection), as oral administration would not allow for proper absorption. This difference from many oral antibiotics ensures that the active ingredient achieves reliable, high concentrations in the body, which is critical for supporting the treatment of established systemic bacterial infections.


What is the General Therapeutic Purpose of Dihydrostreptomycin?

The general therapeutic purpose of Dihydrostreptomycin is to address underlying illnesses caused by susceptible bacteria through its powerful bactericidal action. Its core mechanism involves a precise protein production blockade within the bacterial cell, specifically targeting the 30S ribosomal subunit to corrupt the process of building essential proteins. By halting the bacterial cell's ability to function and replicate, this medicine works to eliminate the pathogenic cause of the infection. This mechanism is crucial in clinical settings where rapid and complete elimination of the pathogen is necessary.

Regulatory References

  1. protein production blockade
  2. 30S ribosomal subunit

What side effects are possible with Citrocil?

Possible side effects and safety information

Official regulatory documents classify adverse reactions to Citrocil (methylcellulose) primarily within the Gastrointestinal System Organ Class. These reactions range from common, expected effects to rare but serious medical emergencies.

Adverse Reactions Scope

Classification Effects (Gastrointestinal Disorders)
Common Gas (flatulence), minor abdominal pain, cramps, and mild bloating.
Serious/Clinically Significant Acute or persistent abdominal pain, vomiting, severe constipation lasting more than three days, and rectal bleeding. These may indicate a serious condition like severe bowel obstruction and require immediate medical attention.

Serious Safety Warnings and Restrictions

Acute Obstruction Risk: Regulatory authorities warn that taking Citrocil without adequate fluid (at least 8 ounces of water or other liquid) can cause the powder to swell rapidly, leading to physical blockage of the throat or esophagus. If chest pain, vomiting, or difficulty breathing or swallowing occurs after taking the product, immediate medical help should be sought.

Allergic Reactions: Serious and potentially fatal hypersensitivity reactions (allergic reactions) are documented. Signs include hives, rash, itching, and swelling of the face, tongue, or throat, or difficulty breathing. The product should be discontinued immediately if any signs of allergic reaction appear.

Contraindications: Citrocil must not be used if a person has: a known or suspected bowel obstruction, difficulty swallowing (dysphagia), symptoms of appendicitis (e.g., unexplained persistent abdominal pain, nausea, or vomiting), or fecal impaction. These conditions define high-risk groups for whom use is strictly prohibited. The regulatory basis for this information stems from government health authorities like the FDA and EMA.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Manifestations

Overdose or excessive exposure to Citrocil (Dihydrostreptomycin Sulfate) is formally documented to result in ototoxicity, which includes both auditory nerve impairment (signs such as tinnitus or hearing loss) and vestibular dysfunction (vertigo, dizziness, and disequilibrium). Additionally, nephrotoxicity is a recognized manifestation, typically evidenced by elevated laboratory findings of blood urea nitrogen (BUN) and serum creatinine. These manifestations are tied to excessive exposure or high plasma concentrations.

Severe Outcomes and Emergency Actions

The most critical outcome is respiratory paralysis, which results from severe neuromuscular blockade and is classified as a life-threatening event. Regulatory guidance mandates that individuals must seek immediate medical attention or call a Poison Control Center in cases of known or suspected overdose. If respiratory paralysis is observed, resuscitative measures should be initiated promptly.

Supportive Care and Monitoring

Overdose treatment is symptomatic and supportive. Supportive measures documented in official labeling include the use of hemodialysis to aid in drug removal from the circulation and the administration of calcium salts as a procedural step to counteract neuromuscular blockade. Monitoring requirements emphasize close clinical observation of renal, auditory, and vestibular functions. The risk of severe neurotoxic reactions is sharply increased in patients with pre-existing impaired renal function.

Therapeutic Uses of Citrocil

What Citrocil Treats: Main Uses and Benefits

Citrocil (Dihydrostreptomycin) is considered relevant in therapeutic areas involving certain severe bacterial infections and is commonly used for managing conditions marked by increased physiological stress. It is relevant in contexts involving heightened systemic burden where initial management strategies may require additional symptomatic support. As the use of Dihydrostreptomycin for human medicine is restricted in some major jurisdictions, the therapeutic benefits are aligned with its closely related analog, Streptomycin. The medicine is applied in therapeutic domains involving certain distressing symptoms caused by susceptible bacteria.

Key Therapeutic Applications

This medicine is applied in specialized clinical settings to address severe systemic illness and conditions associated with critical systemic illness, such as specific types of infective endocarditis. It is also relevant for managing distinct and often rare zoonotic diseases, including Plague and Tularemia. Furthermore, it is commonly used as a component in multi-drug regimens for specialized treatment of drug-resistant Tuberculosis.

The primary therapeutic support helps manage symptoms related to the underlying infection, which supports the patient during difficult episodes by easing distress and contributes to easing the overall symptom load related to disease activity. When the need for additional symptomatic assistance arises, this supportive relief helps patients cope more steadily with symptom fluctuations.

“This medicine is utilized when patients exhibit pronounced signs of infection that may have not been controlled by other symptomatic management strategies.”

Quick Fact: Relief for Systemic Imbalance Citrocil is applied in scenarios where additional management of discomfort is required for symptoms related to systemic imbalance, such as high fever and general toxicity, assisting with symptoms that interfere with daily functioning during acute phases.

Eligibility and Restrictions for Use

Who can and cannot use Citrocil?

The official eligibility profile for Citrocil (Dihydrostreptomycin) is highly restrictive, consistent with the class of aminoglycoside antibiotics. Eligibility is determined strictly by regulatory rules concerning patient physiology and specific conditions.


Eligibility Scope

Category Status According to Regulatory Documents
Populations for whom use is allowed Adults and pediatric patients for certain severe systemic infections (e.g., Plague, Tularemia) where approved by local authorities.
Populations for whom use is contraindicated Patients with a history of hypersensitivity to streptomycin or other aminoglycosides; patients who are pregnant.
Age-related eligibility rules Use requires caution in very young infants and patients older than 60 years of age due to increased toxicity risks.
Condition-specific eligibility rules Use is highly restricted in patients with impaired renal function or pre-existing auditory/VIII cranial nerve dysfunction.
Pregnancy and lactation eligibility Use is contraindicated in pregnancy due to the risk of fetal harm; during lactation, the decision requires weighing the importance of the drug against potential risk to the infant.

Eligibility Classifications (High-Level)

  • Eligibility severity classification: Contraindicated (Hypersensitivity, Pregnancy); Conditional Use (Impaired Renal Function, Advanced Age).

Connection to the overall eligibility profile:

Official regulatory documents define a narrow eligible population by prohibiting use in patients with known allergies or who are pregnant. For all other allowed populations, eligibility is conditional, requiring special consideration and caution when patients present with conditions that may affect drug clearance, such as kidney impairment or advanced age.

What should I know about interactions with other medicines?

️ Interactions that Increase Toxicity Risk

The official regulatory documents for Citrocil (Dihydrostreptomycin) classify its most significant interactions as pharmacodynamic, resulting from additive effects when co-administered with certain other medicinal products. Co-administration with nephrotoxic medicinal products is documented to increase the risk of damage to kidney function. Substances in this category explicitly mentioned in regulatory labels include other aminoglycosides, vancomycin, cisplatin, and cyclosporine. Similarly, the use of ototoxic medicinal products, such as loop diuretics (e.g., furosemide, ethacrynic acid), is officially stated to raise the risk of additive ototoxicity (inner ear damage).

Exposure and Systemic Effects

A related pharmacokinetic constraint is officially documented: when Citrocil is used alongside agents that impair renal function, the medicine's renal clearance is reduced. This failure of elimination leads to increased plasma concentrations (exposure) and a corresponding rise in the risk of toxicity. Separately, the regulatory profile details a heightened risk of potentiation of neuromuscular blockade when Citrocil is co-administered with certain anesthetics or neuromuscular blocking agents. Interaction risks are officially noted as significantly increased in the specific population of patients with pre-existing renal impairment. No interactions with food, alcohol, or herbal products are documented in the prescribing information for this injectable formulation, and no mandatory time-separation rules are listed.

Mechanism of Action

Targeted Blockade of Bacterial Protein Assembly

This domain explains how Dihydrostreptomycin initiates its effect by acting as an inhibitor that physically binds to the bacterial 30S ribosomal subunit. This precise molecular targeting rapidly affects the pathogen's ability to assemble all essential proteins required for viability.


Mechanistic Cascade: Misreading to Cell Death

Following binding, the drug forces the ribosome to misread the genetic code, which results in the synthesis and accumulation of non-functional and toxic proteins inside the bacterial cell. This process is the core mechanistic cascade that leads to the bactericidal effect: the irreversible loss of viability in the susceptible bacterial cell.


⏳ Mechanism Limitations and Environmental Constraints

The mechanism of Dihydrostreptomycin is physiologically constrained because its active transport into the bacterial cell is highly oxygen-dependent. This biological requirement means the drug's effect is lessened in anaerobic (low-oxygen) environments, reducing its ability to reach and bind to the ribosomal target.

Dosage and Administration Information

Official Administration Guidelines for Citrocil

Citrocil (methylcellulose) is for oral administration and must be taken with sufficient fluid to ensure safe and effective use.

Mandatory Procedural Step:

  • Every dose, regardless of formulation, must be taken with at least 8 ounces (a full glass) of water or other fluid. Failure to take the product with adequate fluid may cause it to swell and block the throat or esophagus.
Age Group Formulation Initial Dose Maximum Daily Dose
Adults & Children 12+ years Caplets (500 mg) 2 caplets 12 caplets (up to 6 times per day)
Powder (2g) 1 heaping/rounded tablespoon Up to 3 times per day
Children 6–11 years Caplets (500 mg) 1 caplet 6 caplets (up to 6 times per day)
Powder (2g) 2 to 2.5 level teaspoons Up to 3 times per day
Children under 6 years Consult a physician Consult a physician

Preparation and Timing:

  • Powder formulation requires mixing one dose with a full glass (8 oz) of cold water, stirring briskly, and drinking promptly. Drinking an additional glass of water afterward is helpful.
  • The product is used as-needed at the first sign of irregularity.
  • It should not be used for longer than seven days unless directed by a doctor.

Note on Missed Doses: Instructions for a missed dose are not explicitly documented, as administration is typically on an as-needed basis rather than a fixed regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Citrocil

The research base for Citrocil (Dihydrostreptomycin) consists of studies that evaluate the antibiotic as part of combination treatments for specific, serious bacterial infections. This overview describes what the research has explored and what findings have been reported, according to regulatory and scientific literature.


Evidence for Use in Drug-Resistant Tuberculosis (MDR/RR-TB)

The use of this medicine in regimens for drug-resistant tuberculosis (TB) was studied in clinical research. Studies in this area primarily include Randomized Controlled Trials (RCTs) and large-scale observational cohort studies, which are the types of evidence that regulators examine. These studies monitored specific patient outcomes over defined time intervals, including the time it took for the bacteria to be cleared (a measure of favorable outcome) and the rate at which the infection returned (relapse rates).

The findings describe patterns observed in these large international cohorts. The evidence for the use of this antibiotic class in combination regimens is described as having a high level of consistency and weight.

Evidence for Rare Zoonotic Infections

The research structure for rare diseases typically involves fewer large randomized trials. The evidence for the use of this medicine in conditions like Plague and Tularemia relies mainly on Systematic Reviews of past cases and high-level scientific review.

Studies for Plague (Yersinia pestis)

Research for Plague has explored outcomes in adults and children based largely on historical case reports and public health surveillance data. These studies monitored outcomes related to physiological strain, such as rates of patient survival and the time to fever resolution. The research provides context, but due to the rarity, the evidence level is broadly classified as Moderate for these conditions in scientific reviews.

Studies for Tularemia (Francisella tularensis)

Evidence for Tularemia is derived from systematic reviews of case series and observational data. The research record indicates that certainty for this condition may be lower due to the extreme rarity, which results in smaller study populations and a reliance on retrospective studies.

What Remains Uncertain in the Research

A key limitation is that some findings for Citrocil are inferred from studies involving the broader class of aminoglycoside injectables, meaning that data specific to Dihydrostreptomycin itself is limited in certain areas. Furthermore, the overall evidence quality varies across studies. Results apply only to the specific populations and conditions studied, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Citrocil (FAQ)


Q: Is Citrocil technically a laxative or a fiber supplement?

According to regulatory documents, Citrocil (methylcellulose) is classified as a bulk-forming fiber laxative. It is used to relieve occasional constipation and may help support regularity through its bulk-forming action.

Q: Is bloating or gas considered a normal or expected side effect of Citrocil?

Gas (flatulence), mild bloating, minor abdominal pain, and cramps are officially documented as common adverse reactions. These effects are documented as common reactions that may occur while the body adjusts to the increase in fiber.

Q: What does official regulatory information state about using Citrocil during pregnancy or breastfeeding?

Official information indicates that use during pregnancy is generally considered safe for occasional constipation, provided the product is taken with adequate fluids. For lactation (breastfeeding), data is limited, and consultation with a physician is advised to assist in weighing the product’s importance against potential risks to the infant.

Q: Can Citrocil be safely used by adults over the age of 65?

No absolute contraindication is listed for age alone. However, the label suggests special consideration for patients over 60 years old. This consideration is relevant because the product requires high fluid intake, which may be restricted for patients with certain medical conditions.

Q: Does Citrocil interfere with the absorption of other prescription medications?

The bulk-forming action of the fiber may interfere with the way other oral medications are absorbed by the body. Regulatory advice suggests separating the administration of all oral medications by at least 2 hours before or 2 hours after taking Citrocil. This separation is advised to help minimize the potential for reduced effectiveness of the other medicine.

Q: Can Citrocil be taken alongside medications that are absorbed into the stomach?

Official guidance indicates separating the timing of Citrocil from other oral medications, including those absorbed in the stomach. Taking oral drugs at least 2 hours before or 2 hours after Citrocil helps avoid the possibility of the fiber reducing the absorption or effectiveness of the other medicine.

Q: How is Citrocil's methylcellulose fiber different from the psyllium in other supplements?

Methylcellulose is noted in commercial materials as a fiber that is non-allergenic. This characteristic is noted in commercial materials, based on the fiber's lack of fermentation, differentiating it from some other bulk-forming fibers.

Q: How does the mechanism of action of Citrocil compare to a stool softener?

Citrocil is a bulk-forming laxative that works by swelling with water to increase the size and moisture of the stool. This is a different mechanism from a stool softener, which primarily acts to incorporate fat and water directly into the stool mass.

Q: How long does it typically take for Citrocil to produce an effect?

Official product directions state that Citrocil generally produces a bowel movement within a timeframe of 12 to 72 hours after administration.

Q: Is Citrocil intended for use with occasional constipation or long-term management?

The product is officially used to relieve occasional constipation. Regulatory warnings state that it should not be used for longer than seven days unless guidance is received from a healthcare provider.

Q: Are there any types of food or beverages that should be avoided while taking Citrocil?

While regulatory labeling lists one general food/alcohol/lifestyle interaction risk, it does not specify particular food types or beverages that must be avoided. The primary requirement for safe use is always sufficient fluid intake.

Q: Is there a known interaction between Citrocil and alcohol?

Regulatory documents list a general interaction involving alcohol, food, and lifestyle as a Moderate Potential Hazard. Due to this risk classification, consultation with a healthcare provider is advised regarding the use of Citrocil with alcohol.

Q: Does the sugar-free version of Citrocil contain ingredients that people with PKU should be aware of?

Some methylcellulose products, including certain sugar-free formulations, may contain phenylalanine (a component of aspartame). For patients with Phenylketonuria (PKU), official information suggests verifying the inactive ingredients list and consulting a healthcare provider.

Q: Is Citrocil classified as a stimulant laxative?

No, Citrocil is officially classified as a bulk-forming fiber laxative. This means it works by adding bulk to the stool, which is a different class and mechanism than stimulant laxatives.

Q: Does Citrocil powder need to be taken at a specific time of day?

Official instructions do not mandate a specific time of day for administration. The product is generally directed for use as-needed at the first sign of constipation or irregularity.

Q: How important is it to drink a second full glass of water after mixing the powder?

The regulatory directions emphasize that the first full glass of fluid is mandatory for safe administration. Drinking an additional glass of water afterward is stated to be helpful.

Q: Is Citrocil known to help with symptoms other than constipation, such as lowering cholesterol?

The primary approved use of Citrocil is for constipation. While scientific literature suggests that soluble fibers may influence cholesterol and glucose levels, this is not an approved claim listed on the drug label.

Q: Why is Citrocil often advertised as a fiber that is 'less gassy'?

Commercial product materials state that the methylcellulose fiber will not ferment to cause excess gas. This claim is based on specific laboratory testing, differentiating it from some other forms of bulk-forming fiber.

Q: Is Citrocil a gluten-free product?

The active ingredient, methylcellulose fiber, is noted in commercial materials as a gluten-free fiber.

Q: Is it appropriate to use Citrocil for diarrhea related to certain bowel conditions?

The product is indicated for constipation, including constipation associated with certain other bowel disorders. Its primary use is not for treating diarrhea. The product's use for specific bowel conditions is typically determined by a healthcare provider.

Q: Is there any data on the use of Citrocil in people with chronic kidney disease?

Use in people with renal dysfunction is noted as a Moderate Potential Hazard. This is because the mandatory requirement for high fluid intake may not align with the fluid restrictions sometimes imposed on patients with this condition.

How should Citrocil be stored and disposed of?

Storage and Disposal Requirements for Citrocil

The following conditions are required for the storage and disposal of Citrocil (Dihydrostreptomycin Sulfate) based on official regulatory labeling.

Storage Category Requirement
Unmixed Temperature Store at room temperature, specifically between 20 mathrmC and 25 mathrmC (68 mathrmF and 77 mathrmF).
Environmental Protection The unmixed powder must be protected from light.
Stability After Mixing The reconstituted solution is stable for 24 hours when stored under refrigeration (2 mathrmC to 8 mathrmC).
Child Safety The product must be kept out of the reach of children and pets.
Disposal of Sharps Used needles and syringes must be immediately placed in an FDA-cleared sharps disposal container.
Disposal of Unused Medicine Drug take-back programs are the recommended option. The medicine is not on the FDA's flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Citrocil found in:

A-Z Index: